EIKN EIKN
Company Profile ↓Company Overview
EIKN (EIKN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -36.33% |
| 6 Months: | - |
| 3 Months: | -7.10% |
| 1 Month: | -17.67% |
- Price vs 50-DMABelow
- RSI (14)46.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 41.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 67.78M | 71.38M | 83.17M | 87.34M |
| Operating Income | -67.78M | -71.38M | -83.17M | -87.34M |
| EBITDA | -58.70M | -64.92M | -74.60M | -82.22M |
| Interest Expense | 7.00K | - | -48.00K | - |
| Pretax Income | -64.92M | -68.24M | -79.66M | -82.96M |
| Tax Provision | - | - | - | - |
| Net Income | -64.92M | -68.24M | -79.66M | -82.96M |
| Diluted EPS | - | -2.28 | - | -2.46 |
| R&D Expense | - | 56.59M | - | 70.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 265.74M | 260.34M | 338.94M |
| Operating Income | -265.74M | -260.34M | -338.94M |
| EBITDA | -224.21M | -218.39M | -299.24M |
| Interest Expense | 39.00K | 31.00K | 837.00K |
| Pretax Income | -242.00M | -243.81M | -324.25M |
| Tax Provision | - | - | - |
| Net Income | -242.00M | -243.81M | -324.25M |
| Diluted EPS | -7.40 | -7.45 | -6.18 |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -190.85M | -134.80M | -188.52M |
| Investing Cash Flow | 136.95M | 151.35M | -181.34M |
| Financing Cash Flow | 105.81M | 244.00K | 352.05M |
| Capital Expenditure | -28.51M | -84.80M | -46.74M |
| Free Cash Flow | -219.36M | -219.60M | -235.26M |
| Net Change in Cash | 51.91M | 16.80M | -17.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EIKN
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today …
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer…
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Eikon Therapeutics, Inc. (NASDAQ:EIKN) is one of the best up and coming stocks on our list. TheFly reported on June 3 that BofA Securities lowered its…
Eikon Therapeutics to Join the Russell 3000® Index
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment communityMILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage cli…
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, toda…
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continue…
EIKN — Frequently Asked Questions
What is the current share price of EIKN?
As of 2026-08-05 17:25 PDT, EIKN trades at $9.55 on NASDAQ/NYSE. Its 52-week range is $8.36 to $16.26.
What is the P/E ratio of EIKN?
EIKN trades at a trailing price-to-earnings (P/E) ratio of -1.55.
Is EIKN a good stock to buy?
This page provides a data-driven analysis of EIKN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.